Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
Healthcare
$32.43 +0.74%
+$0.18 today
- Market cap
- $1.77B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
52W Low $9.83High $53.65
Volume 1.00M
Average 0.84M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$111.94M
FY 2025 · Annual
Investing Cash Flow
-$170.96M
FY 2025 · Annual
Financing Cash Flow
$275.34M
FY 2025 · Annual
+196.5% YoYCash Flow Statement
USD
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$131.1M
+ D&A$2.4M
+ Stock-Based Comp$16.4M
+ Deferred Tax$0
- Working Capital-$2.3M
+ Other Non-Cash$2.6M
= Operating Cash Flow-$111.9M
- Capex-$794.0K
= Free Cash Flow-$112.7M
Analysis
FY2025 free cash flow is -$112.7M. FCF conversion is 86.0% of net income. Operating cash flow was -$111.9M, with capex of -$794.0K. The largest bridge item is Stock-Based Comp at $16.4M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 | |
| 8-K | Current report | Oct 16, 2026 |
Does MAZE generate free cash flow?
Maze Therapeutics, Inc. (MAZE) generated -$112.73M of free cash flow in fiscal 2025.
How much operating cash flow does MAZE produce?
Operating cash flow was -$111.94M, before capital expenditures of $794,000.00.
Continue the stock analysis
Jump to another research area for this company.